These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29301541)

  • 1. Compounded medication for patients with rare diseases.
    Dooms M; Carvalho M
    Orphanet J Rare Dis; 2018 Jan; 13(1):1. PubMed ID: 29301541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases.
    Vanhoorne V; Peeters E; Van Tongelen I; Boussery K; Wynendaele E; De Spiegeleer B; Remon JP; Vervaet C
    Orphanet J Rare Dis; 2019 Aug; 14(1):186. PubMed ID: 31370862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies.
    AlKhatib HS; Jalouqa S; Maraqa N; Ratka A; Elayeh E; Al Muhaissen S
    BMC Health Serv Res; 2019 Nov; 19(1):816. PubMed ID: 31703672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient safety issues associated with the use of compounded medicines as alternatives to approved pharmaceutical products in Europe and how best practice can improve outcomes.
    Isles M
    Int J Risk Saf Med; 2020; 31(3):133-144. PubMed ID: 32538874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do we need authorized orphan drugs when compounded medications are available?
    Dooms M; Pincé H; Simoens S
    J Clin Pharm Ther; 2013 Feb; 38(1):1-2. PubMed ID: 22973866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Extemporaneous Prescriptions Prescribed by Dermatovenerologists in Latvia and Comparison with Standardized Compounded Preparation Monographs of Germany and USA.
    Kiseļova O; Mauriņa B; Šidlovska V
    Medicina (Kaunas); 2020 Jan; 56(1):. PubMed ID: 31936697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
    Brion F; Nunn AJ; Rieutord A
    Acta Paediatr; 2003 Apr; 92(4):486-90. PubMed ID: 12801118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality, safety and efficacy in the 'off-label' use of medicines.
    Kairuz TE; Gargiulo D; Bunt C; Garg S
    Curr Drug Saf; 2007 Jan; 2(1):89-95. PubMed ID: 18690954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unlicensed pharmaceutical preparations for clinical patient care: Ensuring safety.
    de Wilde S; de Jong MGH; Le Brun PPH; Guchelaar HJ; Schimmel KJM
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):3-8. PubMed ID: 29047193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Extemporaneously Compounded Nasal Preparations Prescribed by Latvian Otorhinolaryngologists and General Practitioners and Comparison with German Formulations.
    Kiselova O; Maurina B; Sidlovska V
    Int J Pharm Compd; 2020; 24(6):491-500. PubMed ID: 33217739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospital Compounding in Nigeria: A Review of Needs, Practice, and Suggestions for Pharmaceutical Dispensing Ciurriculum Development.
    Orubu ESF; Patani BO; Arhewoh MI
    Int J Pharm Compd; 2021; 25(6):475-481. PubMed ID: 34807842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the type and frequency of extemporaneous formulations dispensed in hospital and community pharmacies.
    Ramtoola Z; Catibusic A; Ameen H; Cullen S; Barlow JW
    Explor Res Clin Soc Pharm; 2023 Dec; 12():100380. PubMed ID: 38146320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Drug Content, Stability Analysis, and Qualitative Assessment of Pharmacists' Opinions of Two Exemplar Extemporaneous Formulations.
    Kirkby M; Moffatt K; Rogers AM; McCague PJ; McElnay JC; Quinn C; McCullough LA; Barry J; Donnelly RF
    Molecules; 2020 Jul; 25(13):. PubMed ID: 32640709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription of compounded ophthalmic medications-a pharmacy perspective.
    Weekes L; Ramzan I
    Clin Exp Optom; 2021 Apr; 104(3):406-411. PubMed ID: 32253769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrophilic Ready-to-use Vehicles and Compounded Topical Medications.
    Spennacchio A; Lacassia C; Lopalco A; Lopedota AA; la Forgia FM; Fontana S; Franco M; Denora N
    Int J Pharm Compd; 2024; 28(2):138-145. PubMed ID: 38604140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compounding for animal patients: contemporary issues.
    Lust E
    J Am Pharm Assoc (2003); 2004; 44(3):375-84; quiz 384-6. PubMed ID: 15191248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipophilic Ready-to-use Vehicles and Compounded Topical Medications.
    Lacassia C; Spennacchio A; Lopalco A; Lopedota AA; la Forgia FM; Fontana S; Franco M; Denora N
    Int J Pharm Compd; 2024; 28(2):146-150. PubMed ID: 38604141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacists' Perceptions of the Economic Value of Compounded Pharmaceuticals: A Comparison of Compounded and Commercial Pharmaceuticals in Select Disease States.
    Lobb WB; Wilkin NE; Holmes ER
    Int J Pharm Compd; 2015; 19(6):514-20. PubMed ID: 26891565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extemporaneous compounding activities and the associated informational needs of pharmacists.
    Crawford SY; Dombrowski SR
    Am J Hosp Pharm; 1991 Jun; 48(6):1205-10. PubMed ID: 1858798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.